Olr742 inhibitors represent a specialized class of chemical compounds designed to interact with and inhibit the function of the Olr742 receptor, a protein that is part of the olfactory receptor family. These receptors are integral to the process of olfaction, the sense of smell, which involves the detection of volatile chemical compounds. Olr742, like other olfactory receptors, belongs to the G-protein-coupled receptor (GPCR) superfamily, characterized by their seven transmembrane helical structures. The inhibitors targeting Olr742 function by binding to specific sites on the receptor, preventing its normal interaction with endogenous ligands or odorants. This binding action can alter the receptor's conformation and impede the subsequent signal transduction pathway that normally leads to olfactory perception. The structural specificity of Olr742 inhibitors is crucial, as it determines the binding affinity and selectivity towards the receptor, ensuring that the inhibition is effective and precise.
The design and synthesis of Olr742 inhibitors involve advanced techniques in medicinal chemistry and molecular modeling. These processes typically start with the identification of the receptor's active site through methods such as X-ray crystallography or cryo-electron microscopy. Once the binding site is mapped, chemists can develop molecules with complementary shapes and electronic properties to achieve optimal interaction with the receptor. Various computational tools are employed to predict and enhance the binding affinity and specificity of these inhibitors. The resulting compounds are then synthesized and subjected to rigorous in vitro testing to evaluate their efficacy in inhibiting the Olr742 receptor. These tests involve assessing the compounds' ability to block the receptor's activity without affecting other olfactory receptors, thereby ensuring the inhibitors' specificity. The development of Olr742 inhibitors not only advances our understanding of olfactory receptor function but also contributes to the broader field of GPCR research, offering insights into receptor-ligand interactions and the molecular mechanisms underlying sensory perception.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted receptor tyrosine kinase inhibitor, possibly interfering with angiogenic and oncogenic signaling pathways. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
EGFR inhibitor, may disrupt cell signaling pathways involved in proliferation and survival of cancer cells. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR, EGFR, and RET kinases, potentially affecting angiogenesis and growth signaling. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor, could modulate cytokine signaling involved in various inflammatory and neoplastic diseases. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor, potentially disrupting multiple signaling pathways involved in cell growth and migration. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
BCR-ABL tyrosine kinase inhibitor, may also affect c-kit and PDGFR, altering cell proliferation and apoptosis pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual tyrosine kinase inhibitor of EGFR and HER2, possibly blocking signal transduction pathways critical in cancer cell growth. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
BCR-ABL inhibitor, more selective than Imatinib, may inhibit related signaling for cell proliferation and survival. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially inducing apoptosis in cancer cells by modulating intrinsic pathway signaling. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, may retard cell cycle progression, affecting cell division and proliferation in cancer cells. | ||||||